Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EF-1 Peptide Vaccine
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intravenous, Intramuscular, Transdermal, Intranasal, Oral
01
Overview
EF-1 Peptide Vaccine is an immunostimulant drug initially developed by the National Cancer Institute. It is being investigated for its potential therapeutic use in neoplasms, skin and musculoskeletal diseases, and other unspecified conditions. As an immunostimulant, its mechanism of action involves enhancing the body's immune response to combat these diseases.
- Other names
- EWS-FLI1 fusion peptideEWS-FLI-1 fusion peptideEWS-FLI 1 fusion peptideEF1 peptideEF-1 peptideEF 1 peptideEWS-FLI1 type 1 junction peptideEWS-FLI-1 type 1 junction peptideEWS-FLI 1 type 1 junction peptide
02
Targets
EWS-FLI1 (Ewing sarcoma breakpoint region 1–Friend leukemia virus integration 1 fusion protein)
Beyond the preview
Go deeper on EF-1 Peptide Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EF-1 Peptide Vaccine.